Prefilled syringes (PFS) and autoinjectors are increasingly used to deliver biologic drug products, particularly monoclonal antibodies (mAbs), to improve convenience, compliance, and dosing accuracy. However, these systems face performance and quality challenges such as needle clogging, particularly for high-concentration, viscous, and aggregation-prone formulations. The origins and mechanisms by which device-derived leachables influence clogging and protein stability remain poorly understood. In this study, we investigated zinc (Zn) leaching from rigid needle shields (RNS) and its interactions with a high-concentration dupilumab formulation and common excipients. Inductively coupled plasma-mass spectrometry (ICP-MS) quantification shows that Zn was the predominant metal in RNS batches, and its extraction kinetics depended strongly on time, temperature, and the presence of a routinely utilized surfactant, polysorbate 80 (PS-80). Stressing RNS materials in the dupilumab formulation at 40 °C for 14 days yielded up to 550 μg/mL Zn(II), roughly 100-fold above typical specifications. Isothermal titration calorimetry (ITC) revealed millimolar Zn(II) binding to PS-80 and weaker interaction with buffer components (histidine, arginine, and acetate), which together promote Zn release. Structural modeling identified surface-exposed regions of dupilumab enriched in histidine-, sulfur-, and carboxylic-acid-containing residues that are geometrically arranged to chelate Zn(II), highlighting likely Zn(II) binding motifs. These protein-metal and excipient-metal interactions, along with PS-80 degradation catalyzed by Zn, correlate with increased solution viscosity and the formation of high-molecular-weight species. Zn leaching from RNS and its synergistic interactions with PS-80, buffer components, and the mAb can drive PS-80 degradation, increase viscosity, and promote higher-order protein aggregation, factors that plausibly contribute to needle clogging. Overall, Zn(II) can simultaneously interact with proteins, increasing their propensity to aggregate while degrading the excipients intended to stabilize them against aggregation. Understanding these mechanisms can inform candidate selection, formulation design, and device choice to mitigate protein aggregation and syringe clogging and improve product reliability and therapeutic outcomes.

Perfusion Chinese hamster ovary (CHO) cell culture offers potential benefits over fed-batch cultures, including higher productivity and a reduced production footprint. However, maintaining a stable profile of product quality attributes (PQAs) over the entirety of a perfusion culture has proven to be a challenge across the biopharmaceutical industry, which is critical for ensuring lot-to-lot consistency. A deeper understanding of the underlying molecular mechanisms of PQA variability and productivity can allow for more targeted interventions. In this study, 13C metabolic flux analysis (13C MFA) was performed on perfusion bioreactors at both early and late stage timepoints to identify potential metabolic bottlenecks. Additionally, RNA-level expression of transporters and enzymes throughout metabolism was measured using RNAseq analysis. Central carbon metabolism in late stage culture was found to have significantly higher flux throughout glycolysis and the tricarboxylic acid (TCA) cycle. In nucleotide sugar synthesis pathways, the ratio of GDP-Fucose synthesis flux to GDP-Mannose synthesis flux was reduced at later cell culture stages, indicating a potential bottleneck for maintaining stable profiles of fucosylated and mannosylated glycans. This bottleneck could potentially be explained by changes in expression of the enzymes in these synthesis pathways as well as a limited pool of NADPH. This work represents the first report demonstrating the application of 13C MFA in early and late-stage perfusion cultures, elucidating potential molecular bottlenecks contributing to unstable PQA profiles.

The paradigm for administering protein biologics is increasingly shifting from intravenous infusion to high-concentration subcutaneous delivery, driven by the desire for patient-centric, sometimes self-administered therapies to better manage chronic diseases. However, this trend is constrained by the inter-related biophysical challenges of protein instability and high viscosity that typically emerge at protein concentrations exceeding 100 mg/mL. In this review, we elucidate the underlying mechanisms of protein instability in a molecularly crowded environment of high-concentration formulations, wherein the close proximity of molecules affect protein structure and function through complex, and often competing, interplay of steric excluded volume repulsion and soft interactions including electrostatic, hydrogen-bonding and hydrophobic forces, leading to reversible and irreversible self-association, increased viscosity and meta-stable association pathways such as liquid-liquid phase separation. Consequently, manipulation of these competing intermolecular interactions can enable the development of stable high-concentration protein therapeutics through rational molecular and formulation design approaches that preserve the native state and elevate the energy barrier for aggregation. Here, we explore the multi-faceted strategies to achieve this balance, including rational formulation design with buffers, excipients, and innovative viscosity-reducing agents, alongside protein engineering approaches to create inherently developable molecules. Moreover, the molecular determinants of solution viscosity arising from protein-protein interactions are discussed with particular focus on the role of arginine and its derivatives to disrupt these network-forming interactions and reduce viscosity in a concentration-dependent manner. The discussion extends to advanced delivery strategies, such as non-aqueous protein powder suspensions and aqueous crystalline or amorphous formulations, which circumvent traditional viscosity limits, in part, by reducing bulk solution protein-protein interactions. Finally, the critical interface between drug product and delivery device is examined, highlighting device innovations that enable the injection of viscous liquids and addressing stability risks from silicone oil and metal leachables in prefilled syringes. Ultimately, the successful development of stable, deliverable, high-concentration biologics combination drug products requires an integrated approach that combines mechanistic understanding, protein biophysics, formulation science, and device engineering.

Virus-like particles (VLPs) are a promising modality with extensive applications in prophylactic and therapeutic vaccine design. Human Papillomavirus (HPV) vaccines are one such example where VLP vaccine applications have led to the successful reduction in HPV-associated diseases, such as cervical cancer. Current purification approaches utilize hydroxyapatite (HA) chromatography in bind-and-elute mode to purify HPV VLPs from host-cell impurities such as proteins and nucleic acids, though binding capacity for VLPs is low due to mass transfer limitations related to their large particle size. The intent of this work was to utilize VLP disassembly prior to HA chromatography in order to increase column yield and capacity. Since L1 protein subunits demonstrated weaker binding avidity for HA resin compared to VLPs, this enabled flow-through purification of L1 protein from strongly adsorbed host cell impurities. Mobile phase conditions were evaluated in batch partition screening experiments to determine the optimal conditions for L1 protein recovery with selective clearance of nucleic acid. Dynamic loading studies showed that while nucleic acid removal was equivalent to the VLP purification process, the flow-through process with disassembled L1 protein achieved higher L1 yield and column capacity. Optimal conditions were applied to HA flow-through purification for multiple HPV types with recombinant L1 protein expressed in yeast, demonstrating > 35% increased yield for six of eight types. The purified, disassembled proteins were subsequently reassembled and had comparable product attributes to the VLP purification process. The implementation of disassembly prior to purification also eliminates the requirement to perform a distinct final disassembly/reassembly process after isolating crude VLPs during purification.

During production, harvested cell culture fluid (HCCF) can degrade due to reductases breaking interchain disulfide bonds, forming low molecular weight (LMW) impurities that contain free sulfhydryl and high molecular weight (HMW) impurities through disulfide shuffling. Thus, detecting and quantifying the free sulfhydryl increase in HCCF is critical. Herein, Raman spectroscopy is implemented as a process analytical technology, and multivariate data analysis is applied to characterize and quantify sulfhydryl formation in HCCF with disulfide- containing indicator molecules. Raman spectra qualitatively probe the presence or absence of disulfide bond breakage in antibodies, consistent with offline non-reduced capillary electrophoresis sodium dodecyl sulfate results. Between two antibodies studied, mAb A was identified for a higher risk of antibody reduction where sulfhydryl formation was observed within 16 h, while mAb B did not show similar concerns even after 1 week. The offline measurement of redox potential is below -100 mV in HCCF for mAb A, while the stable mAb B HCCF shows redox potentials above +20 mV. A multivariate partial least squares (PLS) model for quantification is developed using an offline free sulfhydryl assay, applying Raman spectra to predict free sulfhydryl concentration with high accuracy (R-2 >0.98) and expected mean error of 0.677 mM from the offline Ellman's Assay. This work confirms the use of Raman PAT to monitor real-time disulfide reduction, enabling improvements to process understanding and product quality.

Crystalline suspensions of monoclonal antibodies (mAbs) have great potential to improve drug substance isolation and purification on a large scale and to be used for drug delivery via high-concentration formulations. Crystalline mAb suspensions are expected to have enhanced chemical and physical properties relative to mAb solutions delivered intravenously, making them attractive candidates for subcutaneous delivery. In contrast to small molecules, the development of protein crystalline suspensions is not a widely used approach in the pharmaceutical industry. This is mainly due to the challenges in finding crystalline hits and the suboptimal physical properties of the resulting crystallites when hits are found. Modern advances in instrumentation and increased knowledge of mAb crystallization have, however, resulted in higher probabilities of discovering crystal forms and improving their particle properties and characterization. In this regard, physical, analytical characterization plays a central role in the initial steps of understanding and later optimizing the crystallization of mAbs and requires careful selection of the appropriate tools. This contribution describes a novel crystal structure of the antibody pembrolizumab and demonstrates the usefulness of small-angle X-ray scattering (SAXS) for characterizing its crystalline suspensions. It illustrates the advantages of SAXS when used to (i) confirm crystallinity and crystal phase of crystallites produced in batch mode; (ii) confirm crystallinity under various conditions and detect variations in crystal phases, enabling fine-tuning of the crystallizations for phase control across multiple batches; (iii) monitor the physical response and stability of the crystallites in suspension with regard to filtration and washing; and (iv) monitor the physical stability of the crystallites upon drying. Overall, this work highlights how SAXS is an essential tool for mAb crystallization characterization.

The success of modern biopharmaceutical products depends on enhancing the stability of protein therapeutics. Freezing and thawing, which are common thermal stresses encountered throughout the lifecycle of drug substances, spanning protein production, formulation design, manufacturing, storage, and shipping, can impact this stability. Understanding the physicochemical and molecular behaviors of components in biological drug products at temperatures relevant to manufacturing and shipping is essential for assessing stability risks and determining appropriate storage conditions. This study focuses on the stability of high-concentration monoclonal antibody (mAb) pembrolizumab, the drug substance of Keytruda (Merck & Co., Inc., Rahway, NJ, United States), and its excipients in a frozen solution. By leveraging dynamic nuclear polarization (DNP), we achieve more than 100-fold signal enhancements in solid-state NMR (ssNMR), enabling efficient low-temperature (LT) analysis of pembrolizumab without isotopic enrichment. Through both ex situ and in situ ssNMR experiments conducted across a temperature range of 297 to 77 K, we provide insights into the stability of crystalline pembrolizumab under frozen conditions. Importantly, utilizing LT magic-angle spinning (MAS) probes allows us to study molecular dynamics in pembrolizumab from room temperature down to liquid nitrogen temperatures (<100 K). Our results demonstrate that valuable insights into protein conformation and dynamics, crystallinity, and the phase transformations of excipients during the freezing of the formulation matrix can be readily obtained for biological drug products. This study underscores the potential of LT-MAS ssNMR and DNP techniques for analyzing protein therapeutics and vaccines in frozen solutions.

Freezing is commonly encountered during the processing and storage of biomacromolecule products. Therefore, understanding the phase and state transitions in pharmaceutical frozen solutions is crucial for the rational development of biopharmaceuticals. Solid-state nuclear magnetic resonance spectroscopy (ssNMR) was used to analyze solutions containing sodium phosphate buffer, histidine, and trehalose. Upon freezing, crystallization of disodium phosphate hydrogen dodecahydrate (Na2HPO4·12H2O, DPDH) and histidine was identified using 31P and 13C ssNMR, respectively, and confirmed by synchrotron X-ray diffractometry (SXRD). Using histidine as a molecular probe and based on the chemical shifts of atoms of interest, the pH of the freeze concentrate was measured. The unfrozen water content in freeze concentrates was quantified by 1H single pulse experiments. 13C-insensitive nuclei enhancement by polarization transfer (INEPT) and cross-polarization (CP) experiments were used as orthogonal tools to characterize the solutes in a "mobile" and a more "solid-like" state in the freeze-concentrated solutions, respectively. The above analyses were applied to a commercial monoclonal antibody (mAb) formulation of dupilumab. This work further establishes ssNMR spectroscopy as a highly capable biophysical tool to investigate the attributes of biopharmaceuticals and thereby provide insights into process optimization and formulation development.

Developing biological formulations to maintain the chemical and structural integrity of therapeutic antibodies remains a significant challenge. Monoclonal antibody (mAb) crystalline suspension formulation is a promising alternative for high concentration subcutaneous drug delivery. It demonstrates many merits compared to the solution formulation to reach a high concentration at the reduced viscosity and enhanced stability. One main challenge in drug development is the lack of high-resolution characterization of the crystallinity and stability of mAb microcrystals in the native formulations. Conventional analytical techniques often cannot evaluate structural details of mAb microcrystals in the native suspension due to the presence of visible particles, relatively small crystal size, high protein concentration, and multicomponent nature of a liquid formulation. This study demonstrates the first high-resolution characterization of mAb microcrystalline suspension using magic angle spinning (MAS) NMR spectroscopy. Crystalline suspension formulation of pembrolizumab (Keytruda, Merck & Co., Inc., Kenilworth, NJ 07033, U.S.) is utilized as a model system. Remarkably narrow 13C spectral linewidth of approximately 29 Hz suggests a high order of crystallinity and conformational homogeneity of pembrolizumab crystals. The impact of thermal stress and dehydration on the structure, dynamics, and stability of these mAb crystals in the formulation environment is evaluated. Moreover, isotopic labeling and heteronuclear 13C and 15N spectroscopies have been utilized to identify the binding of caffeine in the pembrolizumab crystal lattice, providing molecular insights into the cocrystallization of the protein and ligand. Our study provides valuable structural details for facilitating the design of crystalline suspension formulation of Keytruda and demonstrates the high potential of MAS NMR as an advanced tool for biophysical characterization of biological therapeutics.

Precompetitive collaborations on new enabling technologies for research and development are becoming popular among pharmaceutical companies. The Enabling Technologies Consortium (ETC), a precompetitive collaboration of leading innovative pharmaceutical companies, identifies and executes projects, often with third-party collaborators, to develop new tools and technologies of mutual interest. Here, we report the results of one of the first ETC projects: the development of a user-friendly population balance model (PBM)-based crystallization simulator software. This project required the development of PBM software with integrated experimental data handling, kinetic parameter regression, interactive process simulation, visualization, and optimization capabilities incorporated in a computationally efficient and robust software platform. Inputs from a team of experienced scientists at 10 ETC member companies helped define a set of software features that guided a team of crystallization modelers to develop software incorporating these features. Communication, continuous testing, and feedback between the ETC and the academic team facilitated the software development. The product of this project, a software tool called CrySiV, an acronym for Crystallization Simulation and Visualization, is reported herein. Currently, CrySiV can be used for cooling, antisolvent, and combined cooling and antisolvent crystallization processes, with primary and secondary nucleation, growth, dissolution, agglomeration, and breakage of crystals. This paper describes the features and the numerical methods of the software and presents two case studies demonstrating its use for parameter estimation. In the first case study, a simulated data set is used to demonstrate the capabilities of the software to find kinetic parameters and its goodness of fit to a known solution. In the second case study, the kinetics of an antisolvent crystallization of indomethacin from a ternary solvent system are estimated, providing a practical example of the tool.

The final chemical transformation and isolation in the synthesis of an active pharmaceutical ingredient (API), referred to as the Pure Step, is often chemically simple but scientifically, operationally, and strategically the most challenging. Pure Step development is critical because it is used to determine and support the critical quality attributes (CQAs) for the API, which will have lasting impacts on both the drug substance and drug product processes. This paper will detail specific challenges for the gefapixant (MK-7264) API, which is isolated as a citrate salt crystallized out of methanol and isopropanol. This citrate salt is then formulated via direct compression to make the final dosage form for the patient. This salt crystallization is particularly challenging due to (1) the propensity of the citrate salt crystal to form solvates, (2) the particle size control requirements, and (3) the variability in crude API purity during development (crude API is the starting material for the Pure Step). The project team had to simultaneously execute targeted, rapid process development to support pilot plant API batches, which supplied clinical trials, tech transfer the process to the manufacturing site overseas, and provide requisite experimental data to support characterization and mechanistic understanding. This work has required technical excellence, streamlined collaboration, and flawless communication across the integrated drug substance/drug product space. The comprehensive process development work resulted in the development of a thermodynamically controlled Pure Step crystallization that yields quality gefapixant API for successful and robust drug product processing.

Crystallization is the primary process used to purify synthetic drug substances and intermediates as well as to control bulk properties, including particle size, surface area, and flowability. Accordingly, new or improved tools to aid crystallization design are of central importance to drug development. In this Perspective, we provide a brief review of the state of the art, identify current challenges, and highlight key opportunities within different aspects of crystallization process development for synthetic pharmaceutical compounds.

Amorphous solid dispersions are a promising option for managing compounds with poor aqueous solubility. However, for compounds with high melting points, thermal stability limitations, or poor solubility in volatile solvents, conventional routes of hot melt extrusion or spray drying may not be viable. Co-precipitated amorphous dispersions (cPAD) can provide a solution. For the material studied in this paper, the cPAD material that was seemingly identical to spray dried material in terms of being single phase amorphous (as measured by DSC and XRD ) but showed slower dissolution behavior. It was identified that physical properties of the cPAD material could be improved to enhance wettability and improve dissolution performance. This was achieved by incorporating the cPAD material into a matrix of water soluble excipients generated via evaporative isolation routes. Importantly, this approach appears to offer another route to further increase the drug load in final dosage units and is significant as increased drug loading generally results in slower or incomplete release. Results showed successful proof of concept via in vitro biorelevant dissolution and confirmatory canine pharmacokinetic studies yielding comparable exposure for capsules comprised of conventional spray dried material as well as capsules with elevated drug load comprised of cPAD hierarchical particles.

Direct compression offers a simple route to generate pharmaceutical dosage units and is core to the growing arena of continuous manufacturing. However, direct compression can be untenable for some active materials. This paper will outline three specific challenges API's can present to direct (active pharmaceutical ingredients) compression. The first involves API's having exceedingly high aspect ratio ("needles") or small particle size resulting in low bulk density and poor flow properties. Two additional cases are relatively newer challenges to direct compression driven by the growing need for solubility enhancing formulations, and involve nano-crystalline materials and spray dried amorphous dispersions. Multiple approaches for managing high aspect ratio or micronized API's have been implemented during the crystallization process or via particle coating downstream from API isolation. Fewer options have been reported for the successful conversion of nano-crystalline materials or spray dried amorphous dispersions into materials amenable to direct compression as these materials offer another specific set of challenges. One route that has not been explored that stands to allow continuous drug product processing across a broader product portfolio involves evaluating opportunities at the drug substance/drug product interface. Here, the options achieved through targeted introduction of excipients to the drug substance processing steps during product precipitation and/or isolation from a product slurry are discussed. This approach introduces new opportunities for designing multicomponent particles through productive and inherently continuous processes. This also offers a longer-term potential route to integrate across continuous drug substance processing to continuous drug product processing.

A recently proposed model to determine particle-size distributions (PSDs) from chord length measurements has been applied to different particle morphologies, namely compact, platelet- and rod-shaped particles. To study these systems, chord length distributions (CLDs) were measured at varying particle size and solids concentration for each compound and were subsequently utilized to determine the system-specific parameters. Each model was successfully applied to its respective compound such that the experimental PSDs and model predictions were in good agreement. Moreover, the effect of other variables such as agitation rate and solvent composition was investigated and found to be negligible for the specific systems tested. Finally, potential model optimizations of the general model construct have been studied. Two variants of the CLD compression step, namely principal component analysis and a geometric model have been considered as surrogate models. However, neither of these approaches yielded superior results than the previously proposed approach.

A shift in particle size distribution toward smaller particle sizes has been observed in batches of Compound A Triethanolate, an isolated intermediate of a commercially available active pharmaceutical ingredient, leading to poor deliquoring of the filter cake and longer filtration times, which compromised the overall process cycle time. In the most extreme case, product breakthrough during filtration was observed, leading to significant yield loss. Compound A Triethanolate is crystallized through antisolvent addition/distillation/cooling crystallization in ethyl acetate/water/ethanol. Laboratory experiments were carried out using representative product streams in order to identify the cause for the shift in particle size distribution, which could be attributed to excessive secondary nucleation at an early stage of the process caused by the use of seed particles that have been previously dried under agitation. While statically dried particles exhibit a smooth surface, the surface of particles dried under agitation is severely damaged. Agitation during drying also leads to partial amorphization of the particles. Crystallization kinetics estimated in this work demonstrated that damaged seed particles led to an increase in the level of secondary nucleation. Analysis of historical data confirmed that the shift in particle size distribution coincided with the complete consumption of statically dried seed particles produced in pilot plant batches, thus requiring a switch in seed source to particles dried under agitation produced in manufacturing batches. As static drying is not a viable option in the production of Compound A Triethanolate because of cycle time constraints, a protocol was developed that aims at healing the seed particles to suppress secondary nucleation. Seed particles are slurried in antisolvent ethanol prior to being charged to the reactor as a slurry in order to decrease the level of amorphous content. The size of the particles produced by the subsequent crystallization increased with increasing amount of ethanol used, which can be explained by the increased capacity to dissolve amorphous content of the seed particles during healing. The increase in particle size is accompanied by reduced filter cake resistance and improved deliquoring of the filter cake. In laboratory experiments, the reduction in the filtration time achieved by using healed seed particles exceeded 1 order of magnitude.

The creation of the Enabling Technologies Consortium (ETC) is described. The ETC fosters precompetitive collaborations aimed at the development and evaluation of new enabling technologies for pharmaceutical research and development, with an initial focus on chemistry, manufacturing, and controls. An overview of the structure and function of the new organization, which will carry out its work while remaining mindful of antitrust compliance requirements, is herein presented along with a description of several ongoing development projects.

Rotor-stator wet mills are commonly used in the pharmaceutical industry to reduce particle size and normalize API physical properties as a means to facilitate downstream drug product operations and/or achieve targeted in vivo product performance. Wet milling is robust, relatively easy to use, broadly applicable, and offers both financial and API physical property advantages over dry milling. Historical rotor-stator wet mill technologies are generally capable of achieving particles sizes down to similar to 25 mu m. Newer high-shear wet mills allow for a reduction of particle size down to similar to 10-15 mu m. In addition to the improved particle size reduction, recent wet mill designs better maintain geometric consistency across the product line, thereby providing enhanced scalability. A traditional scale-up approach for wet milling involved maintaining the tip speed of the rotor (assuming constant shear gap and thus constant shear rate) and would generally allow comparable terminal particle size (that near steady-state particle size where particle size reduction drastically slows) across scales. In order to predict the milling time upon scale-up the number of passes, or batch turnover, through the mill was kept constant. However, this prediction of the required milling time was often less successful than the prediction of the terminal particle size. Studies presented here confirmed the importance of maintaining constant rotor tip speed across scales to achieve the predicted terminal particle size and identified the importance of additional parameters to address particle breakage kinetics to allow prediction of the required milling time to achieve the target particle size. Additional aspects of hydrodynamics, shear rates, and equipment properties were assessed as part of these scale-up model optimization efforts. Specific processing parameters evaluated included flow rate, API slurry solids concentration, and starting particle size distribution. Ultimately, the Slot Event Model was developed to incorporate the critical geometric parameters by considering the frequency and the probability of a slot event. In addition to applying the revised model across scales, further model verification was achieved by evaluating custom rotor-stator mill heads. Studies with these custom mill heads provided insight into the importance of mill efficiency and slot events. This, in turn, allowed for more accurate scale-up of not only the terminal particle size but also the milling time required to achieve the target particle size. The success of the optimized model reduces the reliance on in-process controls or at-line testing for determining the end point of milling.

An automated crystallization platform enabled by FTIR and FBRM in combination with automation and chemometrics has provided a versatile tool for efficient crystallization process development. This system allows users to perform a "walkup" operation for routine process evaluation and also execute automated feedback control of crystallization based on a preset supersaturation profile via cooling and/or antisolvent addition. The concept, procedure, and benefits of the PAT-enabled crystallization platform are presented in general terms and then illustrated through several case studies where feedback control is applied to cooling, antisolvent addition, and "fed batch" (hot batch solution charged to lower-temperature seed bed) crystallization.

It is critical to consistently achieve the desired crystal form for an active pharmaceutical ingredient (API) because crystal form may affect the compound's chemical stability, bioavailability, and pharmaceutical processing performance. The extent to which a crystallizing system is driven by growth vs nucleation is dependent upon the level of supersaturation, defined as the difference between solution concentration and solubility. We describe a method for the accurate measurement of real-time supersaturation, which enabled us to develop and optimize an API crystallization via a feedback-control loop based on concentration measurement with online FTIR. In this contribution we discuss a novel extension of the published work [Zhou, G. X.; et al. Cryst. Growth Des. 2006, 6, 892-898] which ensured robust isolation of the thermodynamically most stable crystal form of an API. The system of interest is a monotropic polymorphic system with overlapping metastable zones. In order to ensure exclusive isolation of the desired form within a reasonable cycle time, a three-pronged approach was applied-maximize seed surface area through the use of milled seed, run the crystallization at a high temperature to increase crystal growth rate, and perform the crystallization at a high level of supersaturation relative to the desired, more stable form while keeping the concentration below the equilibrium solubility of the less stable polymorph. By carefully selecting the seed loading, we were also able to dial-in the target particle size directly via a growth-dominated crystallization, thus eliminating the need for post-crystallization product milling. As a result, a robust, efficient, and reliable crystallization process has been achieved to ensure isolation of the desired polymorph at target particle size.